What will the savings be when this drug goes generic?
Will this drug ease the burden on caregivers?
Does this drug benefit healthy people by lowering everyone's risk?
GCEA is a major advancement in our understanding of societal value. Companies and CEOs can commission their own GCEA studies to help protect patient access to these novel and often life-saving treatments by more clearly conveying their value to society.
NPLB's founder, Peter Kolchinsky, addresses misconceptions about value and highlights a plan for how to protect patient access to the medicines we have today while preserving innovation for those still waiting for a cure.
This white paper explains the difference between GCEA and CEA. GCEA is plain english and makes a case for generalizing cost-effectiveness math to avoid undervaluing medicines. Because if we don't do GCEA, then oversimplified health economics math jeopardizes future medical progress and risks saddling society with preventable costs and illness.